Yıl: 2017 Cilt: 23 Sayı: 5 Sayfa Aralığı: 368 - 376 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model

Öz:
BACKGROUND: Blunt thoracic injury often leads to pulmonary contusion and the development of acute respiratory distress syndrome, which carries a high risk of morbidity and mortality, originating from the local and systemic inflammatory states. This study aimed to investigate the local and systemic antiinflammatory effects of levosimendan in rat models of blunt chest trauma.METHODS: A total of 32 Wistar albino rats were randomly assigned to one of the following four groups: control, sham, low-dose levosimendan (LDL) (5 µg/kg loading dose for 10 min and 0.05 µg/kg/min intravenous infusion), and high-dose levosimendan (HDL) (10 µg/kg loading dose for 10 min and 0.1 µg/kg/min intravenous infusion). Blunt chest trauma was induced, and after 6 h, the contused pulmonary tissues were histopathologically and immunohistopathologically evaluated, serum TNF-α, IL-1β, IL-6, and NO levels were biochemically evaluated.RESULTS: The mean arterial pressure was low throughout the experiment in the LDL and HDL groups, with no statistically difference between the groups. Levosimendan reduced the alveolar congestion and hemorrhage, which developed after inducing trauma. Neutrophil infiltration to the damaged pulmonary tissue was also reduced in both the LDL and HDL groups. In rats in which pulmonary contusion (PC) was observed, increased activation of nuclear factor kappa B was observed in the pulmonary tissue, and levosimendan did not reduce this activation. Both high and low doses of levosimendan reduced serum IL-1β levels, and high doses of levosimendan reduced IL-6 and NO levels. TNF-α levels were not reduced.CONCLUSION: In conclusion, the results showed that in a rat model of PC, the experimental agent levosimendan could reduce neutrophil cell infiltration to damaged pulmonary tissues and the systemic expressions of some cytokines (IL-1β, IL-6, and NO), thereby partially reducing and/or correcting pulmonary damage. Systemic inflammatory response that occurs after trauma could also be reduced
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Raghavendran K, Davidson BA, Woytash JA, Helinski JD, Marschke CJ, Manderscheid PA, et al. The evolution of isolated bilateral lung contusion from blunt chest trauma in rats: cellular and cytokine responses. Shock 2005;24:132–8.
  • 2. Oppenheimer L, Craven KD, Forkert L, Wood LD. Pathophysiology of pulmonary contusion in dogs. J Appl Physiol Respir Environ Exerc Physiol 1979;47:718–28.
  • 3. Hoth JJ, Martin RS, Yoza BK, Wells JD, Meredith JW, McCall CE. Pulmonary contusion primes systemic innate immunity responses. J Trauma 2009;67:14–22.
  • 4. Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury 2007;38:1336–45.
  • 5. Fang DQ, Yu T, Wan L. Effect of nuclear factor-kappa B decoy oligodeoxynucleotides on IL-10, IL-13 and nuclear factor-kappa B protein expressions in rabbits with severe lung contusion. Nan Fang Yi Ke Da Xue Xue Bao 2010;30:2284–7.
  • 6. Shapiro H, Kagan I, Shalita-Chesner M, Singer J, Singer P. Inhaled aerosolized insulin: a “topical” anti-inflammatory treatment for acute lung injury and respiratory distress syndrome? Inflammation 2010;33:315–9.
  • 7. Fudala R, Allen TC, Krupa A, Cagle PT, Nash S, Gryczynski Z, et al. Increased levels of nuclear factor κB and Fos-related antigen 1 in lung tissues from patients with acute respiratory distress syndrome. Arch Pathol Lab Med 2011;135:647–54.
  • 8. Erickson SE, Martin GS, Davis JL, Matthay MA, Eisner MD. Recent trends in acute lung injury mortality: 1996-2005. Crit Care Med 2009;37:1574–9.
  • 9. Cohn SM, Dubose JJ. Pulmonary contusion: an update on recent advances in clinical management. World J Surg 2010;34:1959–70.
  • 10. Moreno N, Tavares-Silva M, Lourenço AP, Oliveira-Pinto J, HenriquesCoelho T, Leite-Moreira AF. Levosimendan: The current situation and new prospects. Rev Port Cardiol 2014;33:795–800.
  • 11. Karakus E, Halici Z, Albayrak A, Bayir Y, Aydin A, Unal D, et al. Beneficial pharmacological effects of levosimendan on antioxidant status of acute inflammation induced in paw of rat: involvement in inflammatory mediators. Basic Clin Pharmacol Toxicol 2013;112:156–63.
  • 12. Yasa H, Yakut N, Emrecan B, Ergunes K, Ortac R, Karahan N, et al. Protective effects of levosimendan and iloprost on lung injury induced by limb ischemia-reperfusion: a rabbit model. J Surg Res 2008;147:138–42.
  • 13. Oldner A, Konrad D, Weitzberg E, Rudehill A, Rossi P, Wanecek M. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 2001;29:2185–93.
  • 14. Dubin A, Maskin B, Murias G, Pozo MO, Sottile JP, Barán M, et al. Effects of levosimendan in normodynamic endotoxaemia: a controlled experimental study. Resuscitation 2006;69:277–86.
  • 15. Raghavendran K, Davidson BA, Helinski JD, Marschke CJ, Manderscheid P, Woytash JA, et al. A rat model for isolated bilateral lung contusion from blunt chest trauma. Anesth Analg 2005;101:1482–9.
  • 16. Edens JW, Chung KK, Pamplin JC, Allan PF, Jones JA, King BT, et al. Predictors of early acute lung injury at a combat support hospital: a prospective observational study. J Trauma 2010;69 Suppl 1:81–6.
  • 17. Maier M, Geiger EV, Wutzler S, Lehnert M, Wiercinski A, Buurman WA, et al. Role of lung contusions on posttraumatic inflammatory response and organ dysfunction in traumatized patients. Eur J Trauma Emerg Surg 2009;35:463–9.
  • 18. Miller PR, Croce MA, Bee TK, Qaisi WG, Smith CP, Collins GL, et al. ARDS after pulmonary contusion: accurate measurement of contusion volume identifies high-risk patients. J Trauma 2001;51:223–30.
  • 19. Knöferl MW, Liener UC, Seitz DH, Perl M, Brückner UB, Kinzl L, et al. Cardiopulmonary, histological, and inflammatory alterations after lung contusion in a novel mouse model of blunt chest trauma. Shock 2003;19:519–25.
  • 20. Bamvita JM, Bergeron E, Lavoie A, Ratte S, Clas D. The impact of premorbid conditions on temporal pattern and location of adult blunt trauma hospital deaths. J Trauma 2007;63:135–41.
  • 21. Azoulay E, Darmon M, Delclaux C, Fieux F, Bornstain C, Moreau D, et al. Deterioration of previous acute lung injury during neutropenia recovery. Crit Care Med 2002;30:781–6.
  • 22. Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med 2011;17:293–307.
  • 23. Perl M, Gebhard F, Brückner UB, Ayala A, Braumüller S, Büttner C, et al. Pulmonary contusion causes impairment of macrophage and lymphocyte immune functions and increases mortality associated with a subsequent septic challenge. Crit Care Med 2005;33:1351–8.
APA Ateş G, Yaman F, BAKAR B, Kisa U, Buyukkocak U, Atasoy P (2017). Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model. , 368 - 376.
Chicago Ateş Gökay,Yaman Ferda,BAKAR BULENT,Kisa Ucler,Buyukkocak Unase,Atasoy Pınar Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model. (2017): 368 - 376.
MLA Ateş Gökay,Yaman Ferda,BAKAR BULENT,Kisa Ucler,Buyukkocak Unase,Atasoy Pınar Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model. , 2017, ss.368 - 376.
AMA Ateş G,Yaman F,BAKAR B,Kisa U,Buyukkocak U,Atasoy P Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model. . 2017; 368 - 376.
Vancouver Ateş G,Yaman F,BAKAR B,Kisa U,Buyukkocak U,Atasoy P Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model. . 2017; 368 - 376.
IEEE Ateş G,Yaman F,BAKAR B,Kisa U,Buyukkocak U,Atasoy P "Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model." , ss.368 - 376, 2017.
ISNAD Ateş, Gökay vd. "Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model". (2017), 368-376.
APA Ateş G, Yaman F, BAKAR B, Kisa U, Buyukkocak U, Atasoy P (2017). Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model. Ulusal Travma ve Acil Cerrahi Dergisi, 23(5), 368 - 376.
Chicago Ateş Gökay,Yaman Ferda,BAKAR BULENT,Kisa Ucler,Buyukkocak Unase,Atasoy Pınar Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model. Ulusal Travma ve Acil Cerrahi Dergisi 23, no.5 (2017): 368 - 376.
MLA Ateş Gökay,Yaman Ferda,BAKAR BULENT,Kisa Ucler,Buyukkocak Unase,Atasoy Pınar Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model. Ulusal Travma ve Acil Cerrahi Dergisi, vol.23, no.5, 2017, ss.368 - 376.
AMA Ateş G,Yaman F,BAKAR B,Kisa U,Buyukkocak U,Atasoy P Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model. Ulusal Travma ve Acil Cerrahi Dergisi. 2017; 23(5): 368 - 376.
Vancouver Ateş G,Yaman F,BAKAR B,Kisa U,Buyukkocak U,Atasoy P Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model. Ulusal Travma ve Acil Cerrahi Dergisi. 2017; 23(5): 368 - 376.
IEEE Ateş G,Yaman F,BAKAR B,Kisa U,Buyukkocak U,Atasoy P "Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model." Ulusal Travma ve Acil Cerrahi Dergisi, 23, ss.368 - 376, 2017.
ISNAD Ateş, Gökay vd. "Evaluation of the systemic antiinflammatory effects of levosimendan in an experimental blunt thoracic trauma model". Ulusal Travma ve Acil Cerrahi Dergisi 23/5 (2017), 368-376.